Category Archives: Top Market News
H.C. Wainwright Remains a Buy on Fulcrum Therapeutics (FULC)
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Fulcrum Therapeutics (FULC – Research Report), with a price target of $20.00. The company’s shares closed last Friday at $11.87. According to TipRanks.com, Fein is
BTIG Maintains a Buy Rating on Avita Medical (RCEL)
BTIG analyst Ryan Zimmerman maintained a Buy rating on Avita Medical (RCEL – Research Report) today and set a price target of $41.00. The company’s shares closed last Friday at $21.07. According to TipRanks.com, Zimmerman is a top 100 analyst
RBC Capital Thinks Karyopharm Therapeutics’ Stock is Going to Recover
RBC Capital analyst Brian Abrahams maintained a Buy rating on Karyopharm Therapeutics (KPTI – Research Report) on April 8 and set a price target of $24.00. The company’s shares closed last Friday at $10.02, close to its 52-week low of
Analysts Are Bullish on Top Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Global Blood Therapeutics (GBT)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vertex Pharmaceuticals (VRTX – Research Report) and Global Blood Therapeutics (GBT – Research Report) with bullish sentiments. Vertex Pharmaceuticals (VRTX) RBC Capital
TCR2 Therapeutics (TCRR) Receives a Buy from Mizuho Securities
In a report released yesterday, Mara Goldstein from Mizuho Securities maintained a Buy rating on TCR2 Therapeutics (TCRR – Research Report), with a price target of $51.00. The company’s shares closed last Friday at $22.02. According to TipRanks.com, Goldstein is
Neoleukin Therapeutics (NLTX) Gets a Buy Rating from Mizuho Securities
In a report released yesterday, Mara Goldstein from Mizuho Securities maintained a Buy rating on Neoleukin Therapeutics (NLTX – Research Report), with a price target of $21.00. The company’s shares closed last Friday at $11.97. According to TipRanks.com, Goldstein is
